isaralgagene civaparvovec
Gene therapy / editing
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
Company guidance: regulatory filing expected Q4 2026 (PTC Therapeutics, 29 Oct 2026). “Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 –” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STAAR NCT04046224 · Fabry Disease Registry: NCT04046224 | 1/2 | Incidence of Treatment-emergent Adverse Events (TEAEs) - All (Up to 12 months after the ST-920 infusion); Incidence of Treatment-emergent Adverse Events (TEAEs) - Related to ST-920 (Up to 12 months post ST-920 infusion); Incidence of Treatment-emergent Adverse Events (TEAEs) - Serious (Up to 12 month post ST-920 infusion); Incidence of Treatment-emergent Adverse Events (TEAEs) - Any TEAEs Leading to Study Discontinuation or Withdrawal (Up to 12 month post ST-920 infusion) 2025-04-10 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other Alpha-galactosidase A (GLA / α-Gal A) drugs
Agalsidase beta, Migalastat, pegunigalsidase alfa. Compare all 4 Alpha-galactosidase A (GLA / α-Gal A) drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Fabry Disease: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Isaralgagene Civaparvovec: this drug | Phase 1/2 | Gene therapy / editing | Alpha-galactosidase A (GLA / α-Gal A) | not yet graded | No reviewed efficacy summary in this indication | |
| Agalsidase Beta (Fabrazyme) | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase. | |
| Migalastat (Galafold) | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | Partial signal | NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed | |
| Pegunigalsidase Alfa | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) |
Upcoming events
No upcoming readouts on record for this asset.